Protagonist Therapeutics, Inc. (PTGX)
Pre-Market:
| Previous Close | 31.94 |
| Open | 32.02 |
| Bid | 30.67 x 100 |
| Ask | 30.79 x 400 |
| Day's Range | 30.64 - 32.14 |
| 52 Week Range | 13.72 - 33.34 |
| Volume | |
| Avg. Volume | 559,698 |
| Market Cap | 1.803B |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | 12.10 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral ...
- ACCESSWIRE
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor ...
- ACCESSWIRE
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 [1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis ...
